Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / TLTFF - Theralase Technologies shares positive interim results from Phase II Bladder Cancer study

TLTFF - Theralase Technologies shares positive interim results from Phase II Bladder Cancer study

Theralase Technologies Inc.

(NewsDirect)

Theralase Technologies CEO RogerDuMoulin-White joined Steve Darling from Proactive to share interimdata from a Phase II clinical study designed to treat patientsdiagnosed with Bacillus Calmette-Guérin Unresponsive, Non-MuscleInvasive Bladder Cancer and Carcinoma In-Situ with a patentedinvestigational study drug Ruvidar, subsequently activated by aproprietary investigational study laser system equipped withfiber-optic light emitters and detectors.

DuMoulin-White discussed more about the study and what theinterim data is telling them about the study.

He also talkedabout the company and the other vertical it has with its Cool LaserTherapy which is focused on the research, development, production anddistribution of medical laser technologies for healing pain.

Contact Details

Proactive Investors

+1604-688-8158

na-editorial@proactiveinvestors.com

Copyright (c) 2023 TheNewswire - All rights reserved.

Stock Information
Company Name: Theralase Technologies Inc.
Stock Symbol: TLTFF
Market: OTC
Website: theralase.com
Menu
TLTFF TLTFF Quote TLTFF Short TLTFF News TLTFF Articles TLTFF Message Board
Get TLTFF Alerts

News, Short Squeeze, Breakout and More Instantly...